Florida's latest theme park injury report includes Universal's Epic Universe for first time
Since opening on May 22, Universal's Epic Universe has documented three incidents: two involving dizziness or numbness on the Stardust Racers ride, both in individuals with pre-existing conditions, and one case of chest pain on the Hiccups Wing Gliders ride.
The report also discusses other major theme parks in Florida, in addition to the incidents at Epic Universe.
Between April and July, Disney documented three incidents across its parks, whereas SeaWorld reported two incidents.
According to the data provided, none of the injuries reported in the latest quarterly report were deemed serious.
Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Pvolve Inks Four New Franchise Deals to Boost Expansion
Functional Fitness Brand to Open Six Studios Across U.S. Markets Amid Rising Demand for Smarter Workouts NEW YORK, July 24, 2025 /PRNewswire/ -- Pvolve, the clinically-backed functional fitness franchise that strengthens, stabilizes, and mobilizes your body, continues to build on its national growth trajectory with the signing of four new franchise agreements. The latest expansion will introduce six studios across Highlands Ranch, Colorado; Atlanta North Perimeter, Georgia; Granger, Indiana; and Richmond, Virginia, further strengthening the brand's presence in key U.S. markets. Each new studio will be independently owned and operated by passionate entrepreneurs who are aligned with Pvolve's mission to deliver a smarter, more sustainable approach to fitness. The newly signed franchisees bring diverse professional backgrounds and a shared belief in the power of movement to transform lives: Highlands Ranch, Colo.: Adrianne Rodriguez, a former medical social worker with nearly 20 years of acute care experience, witnessed firsthand the profound impact of chronic illness and preventable conditions on individuals and families. She is bringing Pvolve to Highlands Ranch, eager to provide her community with a sustainable way to move, feel better and live longer, healthier lives. Atlanta North Perimeter, Ga.: Amber Jackson, with a background in marketing, publicity and corporate operations, expands her successful Pvolve presence with a second studio. As a driven entrepreneur and single mother, she's focused on building a business that supports her own balance while inspiring others to thrive, both physically and personally. Granger, Ind.: Lynn Haberland, vice president and COO of Michiana Neurologic Medicine, brings clinical operations expertise and a passion for wellness. Drawn to Pvolve's alignment with functional medicine, she aims to introduce a fitness method that supports sustainable health and movement. Richmond, Va.: Vikas Kapila, a seasoned franchise veteran and management consultant with experience owning consulting and StretchLab franchises, signed a three-unit agreement. Motivated by helping community members invest in themselves, Kapila was attracted to Pvolve's integrated approach to fitness and wellness. "As we grow, we're inspired by the caliber of franchise partners joining our system – leaders who bring strong business experience and are deeply connected to our brand's mission and values," said Julie Cartwright, President of Pvolve. "This next wave of growth reflects our commitment to meeting consumers where they are with a method that truly supports the body in motion through strength, stability and mobility." This expansion builds on Pvolve's most recent partnership with longevity-focused Tally Health, enhancing brand visibility, franchise development and member engagement, which are essential pillars for long-term success. Supported by a robust omnichannel model that integrates in-studio classes, digital streaming and proprietary equipment, Pvolve's franchise partners are uniquely positioned to serve today's wellness-focused consumers amid rising national demand. Franchise opportunities remain available in priority markets across the U.S., including Texas, Florida and North Carolina. Pvolve is actively seeking both single-unit and multi-unit operators who are mission-driven, community-focused and passionate about health and movement. To learn more about franchising with Pvolve, visit About PvolvePvolve is a workout method that redefines fitness with a method built on the principles of strength, mobility, and stability. As the first and only clinically-proven brand in the space, Pvolve continuously sets new standards for women's health in fitness, ensuring results you can see and feel for today and for the long haul. After being introduced to functional fitness in 2017, founder Rachel Katzman was determined to help others experience an approach that respects the body's holistic needs while making you look and feel great. The Pvolve Method is supported by a Clinical Advisory Board of doctors, as well as highly credentialed trainers, to offer effective workouts that help you break a sweat, not your body. In June 2023, world-renowned actress, producer, and director, Jennifer Aniston, officially partnered with Pvolve after falling in love with the method as a member, and referring to it as "transformational." Through its hybrid fitness model, Pvolve can be experienced through a streaming membership that offers over 1,500 on-demand classes, a two-way, live virtual studio, and targeted series, all available via the web and mobile apps. Additionally, Pvolve has 25 physical studio locations across the US and Canada, with more than 50 studios in development. For more information, please visit MEDIA CONTACT: Ashlyn Pinkowski, Fishman Public Relations, apinkowski@ View original content to download multimedia: SOURCE Pvolve
Yahoo
14 minutes ago
- Yahoo
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, we will summarize the bulls' thesis on VKTX. Viking Therapeutics, Inc. 's share was trading at $32.07 as of July 17th. Viking Therapeutics (VKTX), a ~$3.45B biotech firm, is flying under the radar despite its potentially transformative role in the obesity treatment market. The investment thesis centers on VK2735, a GLP-1/GIP dual agonist for weight loss, being developed in both subcutaneous (Phase 3) and oral (Phase 2) forms—mirroring the mechanism of Eli Lilly's Mounjaro. The oral formulation's Phase 2 data is expected between late July and early September 2025, with projections pointing to best-in-class efficacy and safety. The obesity drug market, with estimates ranging from $95B to $158B by the early 2030s, presents a massive TAM. If VKTX captures even a modest share, its valuation could soar: base case implies $180/share on $5B in revenue, with a bull case of $360–540/share. The stock appears undervalued relative to its potential, trading at a steep discount despite having no debt, $852M in cash, and institutional ownership above 70%. A recent manufacturing agreement with CordenPharma secures scalable production capacity, de-risking the commercial path. Speculation of a buyout—possibly by Pfizer, which exited its own GLP-1 program—adds to the near-term catalysts. While bears raise concerns over market share and scale, the company has mitigated operational risks and may command premium terms in any M&A scenario. Despite its -48% decline over the past year, largely attributed to macro and short interest (~30%), VKTX offers an unusually asymmetric setup. With a potentially dominant pipeline and clear strategic optionality, VKTX stands as one of the most compelling high-risk/high-reward biotech investments today. Previously, we covered a on Viking Therapeutics, Inc. (VKTX) by Kontra Investments in February 2025, which highlighted the strong efficacy and superior safety of VK2735 in both subcutaneous and oral forms. The company's stock price has appreciated approximately by 13% since our coverage. Dritzz-9966 shares a similar view but emphasizes on near-term catalysts and asymmetric risk/reward potential. Viking Therapeutics, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held VKTX at the end of the first quarter which was 42 in the previous quarter. While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip.
UnitedHealth Group (UNH) stock has plummeted nearly 4% in premarket trading after the insurance giant disclosed Department of Justice investigations into its Medicare program participation. The company says it's now complying with formal criminal and civil requests from the DOJ, confirming reports that have contributed to its substantial year-to-date decline of 44.3%. UNH's 50-day moving average is now on the cusp of crossing below its 20-day counterpart, with the shares on pace to revisit their May lows. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! The insurer's Medicare and retirement segment, which includes the Medicare Advantage business, represents its largest revenue stream, having generated $139 billion in sales last year. The negative reaction in the stock today reflects growing investor concerns about potential regulatory risks and compliance costs affecting one of the largest healthcare companies in the United States. What's Driving UNH Stock Down? This development adds to an already challenging period for UnitedHealth, which has been grappling with rising medical costs and a sudden CEO change. Now, the outcome of the DOJ investigation could have further significant material implications for UNH's future operations and financial performance. Despite the ongoing investigation, UnitedHealth cites independent audits by the Centers for Medicare & Medicaid Services that confirm their practices are among the industry's most accurate. Additionally, a court-appointed Special Master has concluded there was no evidence to support claims of wrongdoing in a previous decade-long civil challenge. The company has taken proactive measures by initiating third-party reviews of its policies, practices, and processes related to risk assessment coding, managed care practices, and pharmacy services. What Should UNH Investors Do? The situation presents significant uncertainty for investors, particularly given the critical nature of the Medicare business to UnitedHealth's overall revenue structure. While the company maintains full confidence in its practices and has committed to cooperating with the DOJ throughout the process, the stock's continued decline suggests that investors are pricing in further regulatory downside. However, Wall Street analysts remain surprisingly upbeat on UNH. The number of 'Strong Buy' ratings on the stock stands at 15 out of 24 total recommendations, down from 21 'Strong Buys' a few months ago, for a consensus 'Moderate Buy' from brokerage firms. While UNH stock looks cheap at current levels, trading at a discounted valuation of 13.9x forward earnings, value investors may want to look elsewhere for bargains, as the insurance giant continues to offer a relatively lopsided risk profile with the massive overhang of the DOJ probe. This article was created with the support of automated content tools from our partners at Together, our financial data and AI solutions help us to deliver more informed market headline analysis to readers faster than ever. On the date of publication, Elizabeth H. Volk did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
